Written and maintained by CASRAI Editorial Board
Last updated
PE risk stratification (acute pulmonary embolism risk stratification) is the multiparametric clinical, imaging, and biomarker framework used to classify patients with confirmed or suspected acute pulmonary embolism according to their risk of early (in-hospital or 30-day) mortality and hemodynamic collapse. Unlike pre-test diagnostic probability tools (such as the Wells score or Geneva score, which estimate the likelihood of PE before imaging) or surgical prophylaxis models (such as the Caprini Score for VTE Risk Assessment), PE risk stratification is performed immediately upon diagnosis to determine whether a patient requires emergency systemic thrombolysis/embolectomy, intensive care monitoring, standard inpatient anticoagulation, or early outpatient discharge.
In international clinical practice and cardiovascular trials, two complementary frameworks govern acute PE prognostication: the European Society of Cardiology / European Respiratory Society (ESC/ERS 2019) 4-tier mortality model and the American Heart Association (AHA) Massive, Submassive, and Low-Risk classification.
What Is PE Risk Stratification? The ESC 4-Tier Matrix vs. AHA Classification
Both the ESC/ERS 2019 guidelines (Konstantinides et al., European Heart Journal, 2020) and the AHA scientific statements integrate four core physiological dimensions to stratify acute PE severity:
- Hemodynamic Status: Presence or absence of cardiac arrest, obstructive shock (systolic blood pressure
SBP < 90 mmHgor vasopressor requirement to maintainSBP ≥ 90 mmHgdespite adequate filling status, accompanied by end-organ hypoperfusion), or persistent hypotension (SBP < 90 mmHgor a systolic drop of≥ 40 mmHglasting> 15 minutesnot caused by new-onset arrhythmia, hypovolemia, or sepsis). - Clinical Severity Score (PESI or sPESI): Validated clinical comorbidity and vital-sign indices—specifically PESI Class III–V or Simplified PESI (sPESI) ≥ 1.
- Right Ventricular (RV) Dysfunction on Imaging: Evidence of acute pressure overload on Transthoracic Echocardiography (TTE) or Computed Tomography Pulmonary Angiography (CTPA), primarily an RV/LV end-diastolic diameter ratio ≥ 1.0 (or
> 0.9on 4-chamber CTPA reconstruction), right ventricular hypokinesis (McConnell sign), or tricuspid annular plane systolic excursion (TAPSE < 16 mm). - Myocardial Injury / Ventricular Stretch Biomarkers: Elevated high-sensitivity cardiac troponin I or T (
hs-cTnI/hs-cTnTabove institutional 99th percentile cutoff) and elevated natriuretic peptides (BNP > 100 pg/mLorNT-proBNP ≥ 600 pg/mL).
| ESC 2019 Early Mortality Risk Tier | AHA Classification Equivalent | Hemodynamic Instability | PESI Class III–V or sPESI ≥ 1 | RV Dysfunction (TTE or CTPA) | Elevated Cardiac Troponin | 30-Day Mortality & Typical Disposition |
|---|---|---|---|---|---|---|
| High Risk | Massive PE | Present (+) | (+) Not required to calculate in shock | Present (+) | (+) Not required before reperfusion | > 15% mortality: ICU admission; immediate systemic thrombolysis, catheter-directed therapy, or surgical embolectomy. |
| Intermediate-High Risk | Submassive PE (High-Risk Subgroup) | Absent (–) | Present (+) | Present (+) | Present (+) | 3% – 15% mortality: Step-down or ICU telemetry monitoring; parenteral anticoagulation; PERT evaluation for rescue/catheter therapy. |
| Intermediate-Low Risk | Submassive PE (Single-Marker Subgroup) | Absent (–) | Present (+) | Either one positive (+) or both negative (–) (or sPESI = 0 with isolated +RV or +Troponin) | 1% – 3% mortality: Inpatient medical ward admission; standard therapeutic anticoagulation. | |
| Low Risk | Low-Risk PE | Absent (–) | Absent (–) (PESI I–II or sPESI = 0) | Absent (–) | Absent (–) (if tested) | < 1% mortality: Candidate for early hospital discharge (< 24–48 h) or direct outpatient DOAC treatment if Hestia criteria met. |
PESI vs. Simplified PESI (sPESI) Scoring Criteria
In hemodynamically stable patients, clinical risk stratification begins with either the original 11-variable Pulmonary Embolism Severity Index (PESI) (Aujesky et al., 2005) or the 6-item Simplified PESI (sPESI) (Jiménez et al., Archives of Internal Medicine, 2010). Like other emergency medicine and cardiovascular prognostic scores such as the HEART Score, CURB-65 Score, and Framingham Risk Stratification models, sPESI identifies low-risk patients with high negative predictive value (> 98.5% 30-day survival when sPESI = 0):
| Clinical Variable | Original PESI Points | Simplified PESI (sPESI) Points |
|---|---|---|
| Age | +1 point per year of age | +1 point (if Age > 80 years) |
| Male Sex | +10 points | 0 points (not included) |
| History of Cancer | +30 points | +1 point |
| History of Heart Failure | +10 points | +1 point (combined as History of Chronic Cardiopulmonary Disease) |
| History of Chronic Lung Disease | +10 points | |
| Heart Rate (Pulse) ≥ 110 bpm | +20 points | +1 point |
| Systolic Blood Pressure < 100 mmHg | +30 points | +1 point |
| Respiratory Rate ≥ 30 breaths/min | +20 points | 0 points (not included) |
| Temperature < 36.0 °C (96.8 °F) | +20 points | 0 points (not included) |
| Altered Mental Status | +60 points | 0 points (not included) |
| Arterial Oxygen Saturation (SpO2) < 90% | +20 points | +1 point |
- Original PESI Risk Classes: Class I (
≤ 65 points, very low 30-day mortality0%–1.6%), Class II (66–85 points, low mortality1.7%–3.5%), Class III (86–105 points, moderate mortality3.2%–7.1%), Class IV (106–125 points, high mortality4.0%–11.4%), and Class V (> 125 points, very high mortality10.0%–24.5%). - Simplified PESI (sPESI) Cutoffs:
0 points= Low Risk (30-day mortality~1.0%, 95% CI 0.0%–2.1%);≥ 1 point= High Risk (30-day mortality~10.9%), requiring further sub-stratification into Intermediate-Low or Intermediate-High risk using RV imaging and cardiac troponin.
Note on Acute PE vs. Pulmonary Arterial Hypertension (PAH) Risk Stratification: In cardiology queries, PAH risk stratification refers to chronic WHO Group 1 Pulmonary Arterial Hypertension models—specifically the REVEAL 2.0 / REVEAL Lite 2 risk calculator and the ESC/ERS 3-strata (baseline) and 4-strata (follow-up) PAH tables using WHO Functional Class, 6-Minute Walk Distance (6MWD), and BNP/NT-proBNP—whereas acute PE risk stratification governs acute thromboembolic obstruction.
How Is PE Risk Stratification Used in Clinical Research and Informatics Workflows?
Modern hospitals and clinical trial networks operationalize PE risk stratification through automated informatics and multidisciplinary response pathways:
- AI-Enabled CTPA Triage and Automated RV/LV Ratio Measurement: FDA 510(k)-cleared computer-aided triage and notification (CADt) software (such as Aidoc and Viz.ai PE) analyzes CT pulmonary angiograms immediately upon scanner reconstruction, detecting central or segmental filling defects and automatically calculating the axial or 4-chamber
RV/LV diameter ratioto flag submassive RV strain within minutes. - EHR Clinical Decision Support and PERT Activation: Hospital EHR systems integrate automated sPESI calculators with real-time laboratory feeds (
hs-cTnT,NT-proBNP, lactate) and Emergency Severity Index (ESI) triage workflows. When a patient meets Intermediate-High or High-Risk PE criteria, the EHR triggers a single-click alert to the hospital’s multidisciplinary Pulmonary Embolism Response Team (PERT)—convening pulmonology/critical care, interventional cardiology/radiology, cardiothoracic surgery, and hematology. - Clinical Trial Eligibility Stratification: Landmark interventional PE trials—including PEITHO (tenecteplase in intermediate-risk PE), HI-PEITHO, PEERLESS, and STORM-PE—use the exact ESC Intermediate-High Risk definition (normotensive with both imaging RV/LV ≥ 1.0 and elevated cardiac troponin) as their mandatory inclusion boundary.
Frequently Asked Questions
What is PE risk stratification?
PE risk stratification is the clinical process of categorizing patients with acute pulmonary embolism into four 30-day mortality risk tiers—High Risk (Massive), Intermediate-High Risk (Submassive with both RV dysfunction and elevated troponin), Intermediate-Low Risk (Submassive with one or neither marker positive), and Low Risk—by combining hemodynamic vital signs, PESI/sPESI clinical scores, right ventricular imaging, and cardiac biomarkers.
How is PE risk stratification used in clinical research and healthcare?
In clinical care, PE risk stratification guides immediate treatment decisions: High-Risk patients receive emergency reperfusion therapy, Intermediate-High-Risk patients undergo ICU/telemetry monitoring and Pulmonary Embolism Response Team (PERT) evaluation, and Low-Risk patients (PESI Class I–II or sPESI = 0 without RV strain) are candidates for early discharge on direct oral anticoagulants. In clinical trials, these exact tiers define patient eligibility for catheter-directed thrombectomy and thrombolysis studies.
Why does the 2019 ESC guideline recommend assessing RV function even when sPESI is 0?
Observational registry and meta-analysis data demonstrated that a subset of patients with a clinical score of sPESI = 0 still exhibit silent right ventricular dilation on CTPA or elevated high-sensitivity troponin, which increases early adverse outcomes. Under the 2019 ESC guidelines, if RV dysfunction or elevated troponin is present on routine testing, the patient is reclassified from Low Risk to Intermediate-Low Risk.
